BioAtla, Inc. (NASDAQ:BCAB) Short Interest Update

BioAtla, Inc. (NASDAQ:BCAB) saw a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 4,341,741 shares, a decrease of 29.9% from the November 30th total of 6,190,599 shares. Approximately 8.4% of the company’s shares are short sold. Based on an average daily volume of 989,384 shares, the days-to-cover ratio is currently 4.4 days. Based on an average daily volume of 989,384 shares, the days-to-cover ratio is currently 4.4 days. Approximately 8.4% of the company’s shares are short sold.

Institutional Trading of BioAtla

Large investors have recently bought and sold shares of the business. Woodline Partners LP bought a new position in BioAtla in the first quarter valued at approximately $26,000. Acadian Asset Management LLC raised its holdings in shares of BioAtla by 968.9% during the first quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock worth $585,000 after acquiring an additional 1,531,994 shares during the period. Acorn Capital Advisors LLC raised its holdings in shares of BioAtla by 19.9% during the second quarter. Acorn Capital Advisors LLC now owns 4,835,111 shares of the company’s stock worth $1,915,000 after acquiring an additional 803,065 shares during the period. Sheets Smith Investment Management bought a new stake in BioAtla in the 3rd quarter valued at $46,000. Finally, Vanguard Group Inc. boosted its stake in BioAtla by 9.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock worth $1,339,000 after purchasing an additional 162,647 shares during the period. 77.23% of the stock is owned by institutional investors.

BioAtla Stock Down 8.5%

Shares of BCAB stock opened at $0.72 on Wednesday. BioAtla has a 12-month low of $0.24 and a 12-month high of $1.43. The firm has a fifty day moving average of $0.79 and a 200-day moving average of $0.61. The firm has a market capitalization of $42.15 million, a price-to-earnings ratio of -0.62 and a beta of 1.01.

BioAtla (NASDAQ:BCAB) last posted its earnings results on Thursday, November 13th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.04. Research analysts expect that BioAtla will post -1.46 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Wall Street Zen upgraded BioAtla to a “sell” rating in a report on Saturday, September 6th. Weiss Ratings restated a “sell (d-)” rating on shares of BioAtla in a report on Tuesday, October 14th. Three research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, BioAtla currently has a consensus rating of “Reduce”.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.